NNVC Quote, Financials, Valuation and Earnings

Matinas BioPharma Holdings has a net margin of -- compared to Nanoviricides's net margin of --. Nanoviricides's return on equity of -- beat Matinas BioPharma Holdings's return on equity of --.

Nanoviricides has a consensus price target of --, signalling upside risk potential of 407.81%. On the other hand Matinas BioPharma Holdings has an analysts' consensus of -- which suggests that it could grow by 4652.85%. Given that Matinas BioPharma Holdings has higher upside potential than Nanoviricides, analysts believe Matinas BioPharma Holdings is more attractive than Nanoviricides.

Nanoviricides has a beta of 0.947, which suggesting that the stock is 5.32% less volatile than S&P 500. In comparison Matinas BioPharma Holdings has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.261%.

Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Matinas BioPharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. Matinas BioPharma Holdings pays out -- of its earnings as a dividend.

Nanoviricides quarterly revenues are --, which are smaller than Matinas BioPharma Holdings quarterly revenues of --. Nanoviricides's net income of -$2M is higher than Matinas BioPharma Holdings's net income of -$4.3M. Notably, Nanoviricides's price-to-earnings ratio is -- while Matinas BioPharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus 0.72x for Matinas BioPharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Nanoviricides's net margin of -49.65%. Nanoviricides's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Nanoviricides has a consensus price target of --, signalling upside risk potential of 407.81%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 54.52%. Given that Nanoviricides has higher upside potential than NovaBay Pharmaceuticals, analysts believe Nanoviricides is more attractive than NovaBay Pharmaceuticals.

Nanoviricides has a beta of 0.947, which suggesting that the stock is 5.32% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Nanoviricides quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Nanoviricides's net income of -$2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Nanoviricides's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Nanoviricides's net margin of --. Nanoviricides's return on equity of -- beat Oragenics's return on equity of --.

Nanoviricides has a consensus price target of --, signalling upside risk potential of 407.81%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 455.56%. Given that Oragenics has higher upside potential than Nanoviricides, analysts believe Oragenics is more attractive than Nanoviricides.

Nanoviricides has a beta of 0.947, which suggesting that the stock is 5.32% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Nanoviricides quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Nanoviricides's net income of -$2M is higher than Oragenics's net income of -$3.3M. Notably, Nanoviricides's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus 1.21x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Nanoviricides's net margin of --. Nanoviricides's return on equity of -- beat Theriva Biologics's return on equity of --.

Nanoviricides has a consensus price target of --, signalling upside risk potential of 407.81%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1252.66%. Given that Theriva Biologics has higher upside potential than Nanoviricides, analysts believe Theriva Biologics is more attractive than Nanoviricides.

Nanoviricides has a beta of 0.947, which suggesting that the stock is 5.32% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Nanoviricides has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanoviricides pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Nanoviricides quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Nanoviricides's net income of -$2M is higher than Theriva Biologics's net income of -$4.4M. Notably, Nanoviricides's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanoviricides is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.